Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Royal Marsden Hospital

Comparing selpercatinib and pralsetinib in RET-positive NSCLC
1:19
Comparing selpercatinib and pralsetinib in RET-positive NSCLC
Sanjay Popat • 29 May 2026
AcceleRET-Lung: pralsetinib vs SOC in first-line RET fusion-positive NSCLC
6:11
AcceleRET-Lung: pralsetinib vs SOC in first-line RET fusion-positive NSCLC
Sanjay Popat • 29 May 2026
Elucidating the novel standard of care for EGFR-positive lung cancer
1:52
Elucidating the novel standard of care for EGFR-positive lung cancer
Sanjay Popat • 13 Nov 2025
Systemic therapy options for patients with NSCLC who relapse
2:45
Systemic therapy options for patients with NSCLC who relapse
Sanjay Popat • 13 Nov 2025
Enhancing survivorship and long-term management of ALK+ NSCLC
2:42
Enhancing survivorship and long-term management of ALK+ NSCLC
Sanjay Popat • 13 Nov 2025
Beamion LUNG-1: first-line zongertinib in advanced HER2-mutant NSCLC
2:00
Beamion LUNG-1: first-line zongertinib in advanced HER2-mutant NSCLC
Sanjay Popat • 11 Nov 2025
5-year follow-up of CheckMate 648: NIVO plus chemo or IPI vs chemo as 1L treatment for advanced ESCC
1:27
5-year follow-up of CheckMate 648: NIVO plus chemo or IPI vs chemo as 1L treatment for advanced ESCC
Ian Chau • 20 Oct 2025
SKYSCRAPER-07: atezolizumab with or without tiragolumab in patients with unresectable ESCC
3:08
SKYSCRAPER-07: atezolizumab with or without tiragolumab in patients with unresectable ESCC
Ian Chau • 20 Oct 2025
What does the future hold for ctDNA testing in lung cancer?
1:58
What does the future hold for ctDNA testing in lung cancer?
Sanjay Popat • 18 Sep 2025
Rolling out ctDNA ‘blood-first’ testing for lung cancer in England
2:54
Rolling out ctDNA ‘blood-first’ testing for lung cancer in England
Sanjay Popat • 18 Sep 2025
Treating patients with NSCLC who relapse on osimertinib-based therapies
1:19
Treating patients with NSCLC who relapse on osimertinib-based therapies
Sanjay Popat • 17 Sep 2025
MARIPOSA: resistance mechanisms of amivantamab & lazertinib in NSCLC
3:12
MARIPOSA: resistance mechanisms of amivantamab & lazertinib in NSCLC
Sanjay Popat • 17 Sep 2025
ASCO 2024: key updates in gastric, colorectal, and hepatocellular cancer treatments
0:40
ASCO 2024: key updates in gastric, colorectal, and hepatocellular cancer treatments
Ian Chau • 2 Jun 2024
45-month CheckMate 648 results show nivolumab combos' sustained benefits in ESCC
0:37
45-month CheckMate 648 results show nivolumab combos' sustained benefits in ESCC
Ian Chau • 2 Jun 2024
Long-term efficacy of nivolumab combinations in advanced ESCC in CheckMate 648
1:01
Long-term efficacy of nivolumab combinations in advanced ESCC in CheckMate 648
Ian Chau • 2 Jun 2024
Biomarker-driven approaches for anal cancer
0:49
Biomarker-driven approaches for anal cancer
Sheela Rao • 5 Jul 2023
The content of VJOncology is intended for healthcare professionals